Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 3 Interventional

Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients: The RENAISSANCE Trial

ClinicalTrials.gov ID: NCT07944326

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07944326. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients (RENAISSANCE): A Randomized, Placebo-controlled, Double Blinded, Multicenter Clinical Trial of Sotagliflozin Versus Placebo

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will examine whether sotagliflozin, a medication that may protect the heart and kidneys, can improve long-term health in people who have received a kidney transplant. The study will compare sotagliflozin with an inactive placebo in approximately 900 adult kidney transplant recipients. Researchers will assess whether the medication can reduce the risk of kidney transplant failure, worsening kidney function, heart problems, stroke, heart attack, heart failure, and death. The study will also closely monitor participants for possible side effects, including infections, dehydration, fractures, and rejection of the transplanted kidney.

Study identification

NCT ID
NCT07944326
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 3
Enrollment
900 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 1, 2027 (Estimated)
Primary completion
Oct 1, 2031 (Estimated)
Completion
Mar 1, 2032 (Estimated)
Last update posted
Nov 18, 2026

2027 – 2032

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
University of Minnesota Minneapolis Minnesota 55455 —
NewYork-Presbyterian / Weill Cornell Medical Center New York New York 10065 —
UNC Medical Center Chapel Hill North Carolina 27514 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07944326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 18, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.